Noncompetitive Inhibition of Hepatocyte Growth Factor-dependent Met Signaling by a Phage-derived Peptide
Authors:
- Steven T. RunyonSRSteven T. Runyon
- Lydia SantellLSLydia Santell
- Clifford QuanCQClifford Quan
- Xiaoyi YaoXYXiaoyi Yao
- Daniel KirchhoferDKDaniel Kirchhofer
- Nicholas J. SkeltonNSNicholas J. Skelton
- Robert A. LazarusRLRobert A. Lazarus
- 1 January 2009
- journal article
- Published by Elsevier in Journal of Molecular Biology
- Vol. 385 (1) , 79-90
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Drug development of MET inhibitors: targeting oncogene addiction and expedienceNature Reviews Drug Discovery, 2008
- The Met pathway: master switch and drug target in cancer progressionThe FASEB Journal, 2006
- Targeting the c-Met Signaling Pathway in CancerClinical Cancer Research, 2006
- c-Met as a target for human cancer and characterization of inhibitors for therapeutic interventionCancer Letters, 2005
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- Scatter-factor and semaphorin receptors: cell signalling for invasive growthNature Reviews Cancer, 2002
- Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene ProductScience, 1991
- Molecular cloning and expression of human hepatocyte growth factorNature, 1989
- Tyrosine kinase receptor indistinguishable from the c-met proteinNature, 1989
- Scatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature, 1987